{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"30.0","value":"6.5"},{"groupId":"OG001","lowerLimit":"1.7","upperLimit":"29.9","value":"7.0"},{"groupId":"OG002","lowerLimit":"1.7","upperLimit":"30.0","value":"7.0"}]}]}],"denomUnitsSelected":"Number of Surgeries","denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"26"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"27"}],"units":"Number of Surgeries"}],"description":"Thirty participants who underwent surgery (31 surgeries) were determined to have neuropathic pain (NP). Four participants received only opioids for NP and 26 participants (for 27 surgeries) were treated with NP specific medications including gabapentin, tricyclic antidepressant, methadone. One participant had 2 different surgical procedures and was analyzed both in the limb sparing group and in the amputation group.","dispersionType":"Full Range","groups":[{"description":"Participants had metastatic disease at diagnosis.","id":"OG000","title":"Amputation Group"},{"description":"Participants had localized disease at diagnosis. One participant had 2 surgeries.","id":"OG001","title":"Limb Sparing Group"},{"description":"Participants enrolled on the study who met the criteria for evaluation of neuropathic pain.","id":"OG002","title":"Entire Study Group"}],"paramType":"MEDIAN","populationDescription":"All participants who met the criteria, had surgery, experienced neuropathic pain and were treated with NP medication.","reportingStatus":"POSTED","timeFrame":"From surgery until resolution of NP symptoms, up to 6 months","title":"Median Duration of Neuropathic Pain Medication","type":"OTHER_PRE_SPECIFIED","typeUnitsAnalyzed":"Number of Surgeries","unitOfMeasure":"Weeks"}